Skip to content

Study · Animal study (in vivo) · rat · 2003

6 results

Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses.

Lu XY, Barsh GS, Akil H, Watson SJ

The Journal of neuroscience : the official journal of the Society for Neuroscience1 Aug 2003Cited by 178 (Europe PMC)

PMID12944516 (opens in a new tab)PMCIDPMC6740604 (opens in a new tab)DOI10.1523/jneurosci.23-21-07863.2003 (opens in a new tab)PepBankPUB-12944516
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In conscious rats, intracerebroventricular MTII rapidly increased CRH gene transcription in the paraventricular nucleus.

    In plain wordsIn rats, MTII injected into the brain quickly increased CRH gene transcription in the paraventricular nucleus.

    Peptide
    Melanotan II
    Outcome
    IncreaseCRH gene transcription in the PVN
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    Intracerebroventricular injection of melanocortin agonist MTII to conscious and freely moving rats induced a rapid induction of CRH gene transcription in the PVN.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intracerebroventricular MTII increased plasma corticosterone in a dose- and time-dependent manner, with a maximum 30 min after injection.

    In plain wordsIn rats, MTII injected into the brain raised blood corticosterone, with the largest rise 30 minutes after injection.

    Peptide
    Melanotan II
    Outcome
    IncreasePlasma corticosterone
    Study

    ratn: not reported in source

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Measurements

    Time of maximal corticosterone response
    30 min
    after MTII injection

    Source sentences

    Summary
    This effect was accompanied by a rise in plasma corticosterone levels in a dose- and time-dependent manner, with the maximum response observed 30 min after MTII injection.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intracerebroventricular MTII (0.5 nmol) inhibited food intake.

    In plain wordsIn rats, MTII injected into the brain reduced food intake.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.5 nmol · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    inhibitory effect of MTII (0.5 nmol) on food intake was reversed by pretreatment with alpha-helical-CRH9-41 at 0.25 and 0.5 nmol doses.
    1 context sentence
    Summary · context
    Moreover, the anorectic effect of MTII was evaluated at 1, 2, and 24 hr after intracerebroventricular injection.

Studies that did not test the peptide alone3

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 04AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, the selective MC4R antagonist HS014 attenuated the MTII-induced increase in plasma corticosterone in a dose-dependent manner.

    In plain wordsIn rats, the MC4R blocker HS014 reduced the corticosterone rise that MTII caused, in a dose-dependent way.

    Peptide
    Melanotan II
    Outcome
    DecreaseCorticosterone rise induced by MTII, with MC4R antagonist HS014
    Study

    ratn: not reported in source

    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    MTII (0.5 nmol)-induced increase in plasma corticosterone was attenuated by the selective MC4R antagonist HS014 (0.25-1.0 nmol) and nonselective CRH receptor antagonist alpha-helical-CRH9-41 (0.125-0.5 nmol) in a dose-dependent manner.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 05AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, the nonselective CRH receptor antagonist alpha-helical-CRH9-41 attenuated the MTII-induced increase in plasma corticosterone in a dose-dependent manner.

    In plain wordsIn rats, a CRH receptor blocker reduced the corticosterone rise that MTII caused, in a dose-dependent way.

    Peptide
    Melanotan II
    Outcome
    DecreaseCorticosterone rise induced by MTII, with CRH receptor antagonist
    Study

    ratn: not reported in source

    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    MTII (0.5 nmol)-induced increase in plasma corticosterone was attenuated by the selective MC4R antagonist HS014 (0.25-1.0 nmol) and nonselective CRH receptor antagonist alpha-helical-CRH9-41 (0.125-0.5 nmol) in a dose-dependent manner.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  3. 06AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, pretreatment with alpha-helical-CRH9-41 reversed about half of the MTII-induced inhibition of food intake.

    In plain wordsIn rats, a CRH receptor blocker undid about half of the reduction in food intake that MTII caused.

    Peptide
    Melanotan II
    Outcome
    IncreaseMTII-induced inhibition of food intake, with CRH receptor antagonist
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Approximately half of the inhibitory effect of MTII (0.5 nmol) on food intake was reversed by pretreatment with alpha-helical-CRH9-41 at 0.25 and 0.5 nmol doses.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.